TY - JOUR PY - 1996 DA - 1996// TI - Guidelines for monitoring drug therapy in rheumatoid arthritis. JO - Arthritis Rheum VL - 39 UR - https://doi.org/10.1002/art.1780390503 DO - 10.1002/art.1780390503 ID - ref1 ER - TY - JOUR PY - 1996 DA - 1996// TI - Guidelines for the management of rheumatoid arthritis. JO - Arthritis Rheum VL - 39 UR - https://doi.org/10.1002/art.1780390502 DO - 10.1002/art.1780390502 ID - ref2 ER - TY - JOUR AU - Wolfe, M. M. AU - Lichtenstein, D. R. AU - Singh, G. PY - 1999 DA - 1999// TI - Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/NEJM199906173402407 DO - 10.1056/NEJM199906173402407 ID - Wolfe1999 ER - TY - JOUR AU - Fries, J. F. AU - Williams, C. A. AU - Bloch, D. A. AU - Michel, B. A. PY - 1991 DA - 1991// TI - Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. JO - Am J Med VL - 91 UR - https://doi.org/10.1016/0002-9343(91)90118-H DO - 10.1016/0002-9343(91)90118-H ID - Fries1991 ER - TY - CHAP AU - van Riel, P. L. C. M. AU - Wijnands, M. J. H. AU - van de Putte, L. B. A. ED - Klippel, J. H. ED - Dieppe, P. A. ED - Arnett, F. C. PY - 1998 DA - 1998// TI - Evaluation and management of active inflammatory disease. BT - In: Rheumatology PB - Mosby CY - London ID - van Riel1998 ER - TY - JOUR AU - Bombardier, C. AU - Laine, L. AU - Reicin, A. PY - 2000 DA - 2000// TI - Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. JO - New Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200011233432103 DO - 10.1056/NEJM200011233432103 ID - Bombardier2000 ER - TY - JOUR AU - Schnitzer, T. J. AU - Truitt, K. AU - Fleischmann, R. PY - 1999 DA - 1999// TI - The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. JO - Clinical Therapeutics VL - 21 UR - https://doi.org/10.1016/S0149-2918(99)80048-4 DO - 10.1016/S0149-2918(99)80048-4 ID - Schnitzer1999 ER - TY - JOUR AU - Emery, P. AU - Zeidler, H. AU - Kvien, K. T. PY - 1999 DA - 1999// TI - Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. JO - Lancet VL - 354 UR - https://doi.org/10.1016/S0140-6736(99)02332-6 DO - 10.1016/S0140-6736(99)02332-6 ID - Emery1999 ER - TY - CHAP AU - Matsumoto, A. AU - Melian, A. AU - Mandel, D. R. PY - 2002 DA - 2002// TI - A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis BT - J Rheumatology ID - Matsumoto2002 ER - TY - JOUR AU - Felson, D. T. AU - Anderson, J. J. AU - Boers, M. PY - 1995 DA - 1995// TI - American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. JO - Arthritis Rheum VL - 38 UR - https://doi.org/10.1002/art.1780380602 DO - 10.1002/art.1780380602 ID - Felson1995 ER - TY - JOUR AU - Malmstrom, K. AU - Shahane, A. AU - Fricke, J. R. AU - Ehrich, E. PY - 2000 DA - 2000// TI - MK –0663–an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model. JO - Arthritis Rheum VL - 43 ID - Malmstrom2000 ER - TY - JOUR AU - Gottesdiener, K. AU - Schnitzer, T. AU - Fisher, C. PY - 1999 DA - 1999// TI - MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee. JO - Arthritis Rheum VL - 42 ID - Gottesdiener1999 ER - TY - JOUR AU - Gottesdiener, K. AU - Schnitzer, T. AU - Fisher, C. PY - 2000 DA - 2000// TI - Treatment with MK-663, a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee that was sustained over three months. JO - Ann Rheum Dis VL - 59 ID - Gottesdiener2000 ER - TY - JOUR AU - Brater, D. C. AU - Harris, C. AU - Redfern, J. S. AU - Gertz, B. J. PY - 2001 DA - 2001// TI - Renal effects of COX-2-selective inhibitors. JO - Am J Nephrol VL - 21 UR - https://doi.org/10.1159/000046212 DO - 10.1159/000046212 ID - Brater2001 ER - TY - JOUR AU - Murray, M. D. AU - Brater, D. C. PY - 1993 DA - 1993// TI - Renal toxicity of the nonsteroidal anti-inflammatory drugs. JO - Annu Rev Pharmacol Toxicol VL - 32 UR - https://doi.org/10.1146/annurev.pa.33.040193.002251 DO - 10.1146/annurev.pa.33.040193.002251 ID - Murray1993 ER - TY - JOUR AU - Langman, M. J. AU - Jensen, D. M. AU - Watson, D. J. PY - 1999 DA - 1999// TI - Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JO - JAMA VL - 282 UR - https://doi.org/10.1001/jama.282.20.1929 DO - 10.1001/jama.282.20.1929 ID - Langman1999 ER - TY - JOUR AU - Catella-Lawson, F. AU - Crofford, L. J. PY - 2001 DA - 2001// TI - Cyclooxygenase inhibition and thrombogenicity. JO - Am J Med VL - 110 UR - https://doi.org/10.1016/S0002-9343(00)00683-5 DO - 10.1016/S0002-9343(00)00683-5 ID - Catella-Lawson2001 ER - TY - JOUR AU - Mukherjee, D. AU - Nissen, S. E. AU - Topol, E. J. PY - 2001 DA - 2001// TI - Risk of cardiovascular events associated with selective cox-2 inhibitors. JO - JAMA VL - 286 UR - https://doi.org/10.1001/jama.286.8.954 DO - 10.1001/jama.286.8.954 ID - Mukherjee2001 ER - TY - JOUR AU - Curtis, S. P. AU - Maldonado-Cocco, J. AU - Lozada, B. PY - 2000 DA - 2000// TI - Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis. JO - Arthritis Rheum VL - 43 UR - https://doi.org/3.0.CO;2-Q DO - 3.0.CO;2-Q ID - Curtis2000 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2296/3/10/prepub UR - http://www.biomedcentral.com/1471-2296/3/10/prepub ID - ref20 ER -